DarioHealth Corp. (DRIO)

NCM – Real vaqt narxi. Valyuta: USD

8.68

+0.70 (8.77%)

Yopilishda: May 12, 2026, 4:00 PM EDT

8.87

+0.19 (2.19%)

Bozor oldidan: May 13, 2026, 8:03 AM EDT

04.05.2026

DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m.

20.04.2026

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payers NEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, titled Enhancing Workplace Outcomes Through Digital Behavioral Health Programs: Retrospective Real–World Study , demonstrated statistically significant improvements in workplace functioning among users of Dario's behavioral health solutions.

13.04.2026

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value NEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.

19.03.2026

DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript

19.03.2026

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to earnings of $0.2 per share a year ago.

19.03.2026

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 2025 2025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $ 12.9 million in contracted and late stage, annual recurring revenue ("ARR") set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectory GAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-GAAP gross margins have sustained at 80% for 2 years on the core B2B2C business Fourth quarter 2025 delivered the lowest operating expense run-rate on both a GAAP and Non-GAAP basis since Twill's acquisition, reducing Non-GAAP operating expenses by 28% year-over-year, from $12.4 million to $9.0 million, leading to continued improvements in operating loss for the fourth quarter and full year Pipeline of commercial opportunities grew to $122 million as of December 31 2025, based on 200+ opportunities that are B2B2C Increased demand for Dario's musculoskeletal ("MSK") product in the B2C market, with 36% growth in the fourth quarter of 2025 and continued expansion expected in international markets Dario will host an investor conference call and webcast at 8:30 a.m. ET today NEW YORK, March 19, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced its financial results for the fourth quarter and full-year 2025, along with strategic and commercial updates.

11.03.2026

DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m.

Videolar

No Data

There is no data to display

Press-relizlar

20.04.2026

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

13.04.2026

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

19.03.2026

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

10.03.2026

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

Findings reinforce that engagement data provide clinical signals directly impacting ROI Analysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curve NEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform. The observational study, titled " Machine learning and engagement insights for personalized blood glucose management ," analyzed real-world data from 22,414 adults with type 2 diabetes and baseline blood glucose levels in the high-risk range.

DarioHealth Corp. (DRIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

DarioHealth Corp. (DRIO)

DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

Videolar

No Data

Press-relizlar

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

Videolar

No Data

Press-relizlar

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

Search stocks

DarioHealth Corp. (DRIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

DarioHealth Corp. (DRIO)

DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

Videolar

No Data

Press-relizlar

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

Videolar

No Data

Press-relizlar

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health